LEADER 01492nas  22005173  450 
001 9910763965303321
005 20231101153601.0
035   $a(OCoLC)190812633
035   $a(CKB)954927623143
035   $a(CONSER)--2015201052
035   $a(DE-599)ZDB2272437-0
035   $a(EXLCZ)99954927623143
100   $a20080115b19781981  s--            a
101 0 $aeng
135   $aurun|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aCancer clinical trials
210  1$aNew York :$cMasson Pub. USA,$d1978-
311 1 $a0190-1206 
531   $aCANCER CLIN TRIALS
531 0 $aCancer clin. trials
606   $aCancer$vPeriodicals
606   $aClinical trials$vPeriodicals
606   $aCancer$2fast$3(OCoLC)fst00845317
606   $aClinical trials$2fast$3(OCoLC)fst00864429
606   $aNeoplasms$xdrug therapy$vPeriodicals
606   $aNeoplasms$xtherapy$vPeriodicals
606   $aNeoplasms$xdrug therapy
606   $aNeoplasms$xtherapy
608   $aPeriodical.
608   $aPeriodicals.$2fast
615  0$aCancer
615  0$aClinical trials
615  7$aCancer.
615  7$aClinical trials.
615  2$aNeoplasms$xdrug therapy
615  2$aNeoplasms$xtherapy
615  2$aNeoplasms$xdrug therapy.
615  2$aNeoplasms$xtherapy.
676   $a616.9/94/005
906   $aJOURNAL
912   $a9910763965303321
996   $aCancer clinical trials$93645051
997   $aUNINA